Trade Edwards Lifesciences - EW CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.22 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Edwards Lifesciences Corp ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 78.06 |
Open* | 77.59 |
1-Year Change* | -28.28% |
Day's Range* | 77.59 - 78.68 |
52 wk Range | 67.13-131.10 |
Average Volume (10 days) | 2.71M |
Average Volume (3 months) | 104.69M |
Market Cap | 48.35B |
P/E Ratio | 33.67 |
Shares Outstanding | 618.26M |
Revenue | 5.36B |
EPS | 2.32 |
Dividend (Yield %) | N/A |
Beta | 1.01 |
Next Earnings Date | Jan 31, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 27, 2023 | 78.04 | -0.05 | -0.06% | 78.09 | 78.75 | 77.59 |
Jan 26, 2023 | 78.06 | 0.41 | 0.53% | 77.65 | 78.39 | 77.12 |
Jan 25, 2023 | 77.59 | 1.68 | 2.21% | 75.91 | 77.64 | 75.43 |
Jan 24, 2023 | 77.02 | -1.99 | -2.52% | 79.01 | 79.61 | 76.91 |
Jan 23, 2023 | 79.95 | 1.02 | 1.29% | 78.93 | 80.68 | 78.74 |
Jan 20, 2023 | 79.21 | 0.35 | 0.44% | 78.86 | 79.25 | 77.54 |
Jan 19, 2023 | 78.34 | 0.96 | 1.24% | 77.38 | 78.83 | 77.15 |
Jan 18, 2023 | 78.19 | -0.59 | -0.75% | 78.78 | 79.34 | 78.02 |
Jan 17, 2023 | 78.72 | 1.01 | 1.30% | 77.71 | 78.88 | 77.31 |
Jan 13, 2023 | 78.16 | 1.41 | 1.84% | 76.75 | 78.32 | 76.75 |
Jan 12, 2023 | 77.60 | 0.52 | 0.67% | 77.08 | 78.15 | 76.03 |
Jan 11, 2023 | 77.56 | 0.57 | 0.74% | 76.99 | 78.38 | 76.55 |
Jan 10, 2023 | 76.92 | 0.93 | 1.22% | 75.99 | 77.43 | 75.67 |
Jan 9, 2023 | 76.26 | -0.70 | -0.91% | 76.96 | 78.15 | 76.21 |
Jan 6, 2023 | 76.86 | 2.00 | 2.67% | 74.86 | 77.04 | 73.79 |
Jan 5, 2023 | 75.07 | -0.28 | -0.37% | 75.35 | 76.35 | 74.90 |
Jan 4, 2023 | 76.36 | 1.52 | 2.03% | 74.84 | 76.44 | 74.02 |
Jan 3, 2023 | 74.14 | -0.94 | -1.25% | 75.08 | 76.74 | 73.72 |
Dec 30, 2022 | 74.48 | 0.28 | 0.38% | 74.20 | 74.57 | 73.26 |
Dec 29, 2022 | 75.09 | 1.69 | 2.30% | 73.40 | 75.34 | 72.76 |
Edwards Lifesciences Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 2963.7 | 3435.3 | 3722.8 | 4348 | 4386.3 | 5232.5 |
Revenue | 2963.7 | 3435.3 | 3722.8 | 4348 | 4386.3 | 5232.5 |
Cost of Revenue, Total | 797.4 | 875.3 | 939.4 | 1114.4 | 1080.6 | 1248.9 |
Gross Profit | 2166.3 | 2560 | 2783.4 | 3233.6 | 3305.7 | 3983.6 |
Total Operating Expense | 2225.8 | 2400.4 | 2967.5 | 3201.2 | 3488.7 | 3542.2 |
Selling/General/Admin. Expenses, Total | 904.7 | 985.8 | 1088.5 | 1240.2 | 1228.4 | 1493.7 |
Research & Development | 443.3 | 552.6 | 622.2 | 752.7 | 760.7 | 903.1 |
Interest Expense (Income) - Net Operating | 8.7 | -1.6 | ||||
Unusual Expense (Income) | 67.1 | -13.4 | 323.1 | 100 | 405.4 | 20.6 |
Other Operating Expenses, Total | 4.6 | 1.7 | -5.7 | -6.1 | 13.6 | -124.1 |
Operating Income | 737.9 | 1034.9 | 755.3 | 1146.8 | 897.6 | 1690.3 |
Net Income Before Taxes | 737.9 | 1034.9 | 761.4 | 1166.5 | 916.7 | 1702 |
Net Income After Taxes | 569.5 | 877.7 | 738 | 1049.7 | 823.4 | 1503.1 |
Net Income Before Extra. Items | 569.5 | 877.7 | 738 | 1049.7 | 823.4 | 1503.1 |
Net Income | 569.5 | 583.6 | 722.2 | 1046.9 | 823.4 | 1503.1 |
Income Available to Common Excl. Extra. Items | 569.5 | 877.7 | 738 | 1049.7 | 823.4 | 1503.1 |
Income Available to Common Incl. Extra. Items | 569.5 | 583.6 | 722.2 | 1046.9 | 823.4 | 1503.1 |
Diluted Net Income | 569.5 | 583.6 | 722.2 | 1046.9 | 823.4 | 1503.1 |
Diluted Weighted Average Shares | 653.407 | 647.706 | 640.806 | 636.606 | 631.9 | 631.2 |
Diluted EPS Excluding Extraordinary Items | 0.87159 | 1.35509 | 1.15167 | 1.6489 | 1.30305 | 2.38134 |
Diluted Normalized EPS | 0.95084 | 1.33754 | 1.64039 | 1.79025 | 1.87932 | 2.41016 |
Total Extraordinary Items | -294.1 | -15.8 | -2.8 | |||
Interest Income (Expense), Net Non-Operating | 17.3 | 21.3 | 20.5 | 9.8 | ||
Other, Net | -11.2 | -1.6 | -1.4 | 1.9 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 1216.6 | 1376 | 1310.2 | 1329.7 | 1341.2 |
Revenue | 1216.6 | 1376 | 1310.2 | 1329.7 | 1341.2 |
Cost of Revenue, Total | 293.4 | 334.3 | 311.7 | 309.5 | 299.3 |
Gross Profit | 923.2 | 1041.7 | 998.5 | 1020.2 | 1041.9 |
Total Operating Expense | 833.1 | 833.9 | 919.9 | 955.3 | 902.4 |
Selling/General/Admin. Expenses, Total | 330.8 | 374.5 | 364.4 | 424 | 370.3 |
Research & Development | 207 | 225.3 | 238 | 232.8 | 228.6 |
Unusual Expense (Income) | 6.4 | 2.4 | 4.7 | 7.1 | 7.1 |
Other Operating Expenses, Total | -4.5 | -102.6 | 1.1 | -18.1 | -2.9 |
Operating Income | 383.5 | 542.1 | 390.3 | 374.4 | 438.8 |
Interest Income (Expense), Net Non-Operating | 4.7 | 3.1 | 0.4 | 1.6 | -4 |
Other, Net | 1.1 | 0.3 | 0.2 | 0.3 | 1.3 |
Net Income Before Taxes | 389.3 | 545.5 | 390.9 | 376.3 | 436.1 |
Net Income After Taxes | 338.2 | 489.5 | 340.1 | 335.3 | 373.6 |
Net Income Before Extra. Items | 338.2 | 489.5 | 340.1 | 335.3 | 373.6 |
Net Income | 338.2 | 489.5 | 340.1 | 335.3 | 373.6 |
Income Available to Common Excl. Extra. Items | 338.2 | 489.5 | 340.1 | 335.3 | 373.6 |
Income Available to Common Incl. Extra. Items | 338.2 | 489.5 | 340.1 | 335.3 | 373.6 |
Diluted Net Income | 338.2 | 489.5 | 340.1 | 335.3 | 373.6 |
Diluted Weighted Average Shares | 631.3 | 629.9 | 631.7 | 631.8 | 629.4 |
Diluted EPS Excluding Extraordinary Items | 0.53572 | 0.77711 | 0.53839 | 0.53071 | 0.59358 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.54453 | 0.78053 | 0.54486 | 0.54072 | 0.60325 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 2240 | 2549.2 | 2286.9 | 2984 | 3091 | 3180.7 |
Cash and Short Term Investments | 1271.1 | 1337.5 | 956.5 | 1516.9 | 1402.6 | 1466.8 |
Cash & Equivalents | 930.1 | 818.3 | 714.1 | 1179.1 | 1183.2 | 862.8 |
Short Term Investments | 341 | 519.2 | 242.4 | 337.8 | 219.4 | 604 |
Total Receivables, Net | 414.6 | 479.3 | 537.3 | 599.1 | 602.8 | 664.9 |
Accounts Receivable - Trade, Net | 414.6 | 438.7 | 456.9 | 543.6 | 514.6 | 582.2 |
Total Inventory | 396.6 | 554.9 | 607 | 640.9 | 802.3 | 726.7 |
Prepaid Expenses | 45.9 | 60.6 | 54.3 | 59.1 | 75.1 | 85.2 |
Other Current Assets, Total | 111.8 | 116.9 | 131.8 | 168 | 208.2 | 237.1 |
Total Assets | 4510 | 5666.4 | 5323.7 | 6488.1 | 7237.1 | 8502.6 |
Property/Plant/Equipment, Total - Net | 580 | 679.7 | 867.5 | 1140.4 | 1489.4 | 1638.7 |
Goodwill, Net | 626.1 | 1126.5 | 1112.2 | 1167.7 | 1173.2 | 1167.9 |
Intangibles, Net | 204.8 | 468 | 343.2 | 336.5 | 331.4 | 323.6 |
Long Term Investments | 532.1 | 567 | 506.3 | 585.5 | 801.6 | 1834.2 |
Other Long Term Assets, Total | 327 | 276 | 207.6 | 274 | 350.5 | 357.5 |
Total Current Liabilities | 532.5 | 1420 | 876.6 | 902.4 | 893.9 | 1032.3 |
Accounts Payable | 97.1 | 116.6 | 134 | 180.4 | 196.5 | 204.5 |
Accrued Expenses | 418.4 | 516.1 | 510.2 | 642.7 | 578.7 | 714.2 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 17 | 189.3 | 232.4 | 79.3 | 118.7 | 113.6 |
Total Liabilities | 1891 | 2710.2 | 2183.3 | 2339.8 | 2662.8 | 2666.7 |
Total Long Term Debt | 822.3 | 438.4 | 593.8 | 594.4 | 595 | 595.7 |
Long Term Debt | 822.3 | 438.4 | 593.8 | 594.4 | 595 | 595.7 |
Other Liabilities, Total | 536.2 | 851.8 | 588 | 671.3 | 959.5 | 779.7 |
Total Equity | 2619 | 2956.2 | 3140.4 | 4148.3 | 4574.3 | 5835.9 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 242.6 | 212 | 215.2 | 218.1 | 636.4 | 642 |
Additional Paid-In Capital | 1167.8 | 1166.9 | 1384.4 | 1623.3 | 1438.1 | 1700.4 |
Retained Earnings (Accumulated Deficit) | 3906.3 | 1962.1 | 2694.7 | 3741.6 | 4565 | 6068.1 |
Treasury Stock - Common | -2499.3 | -252.1 | -1015.4 | -1278.7 | -1904.1 | -2416.9 |
Other Equity, Total | -198.4 | -128.1 | -133.5 | -157.7 | -169.7 | -150.8 |
Total Liabilities & Shareholders’ Equity | 4510 | 5666.4 | 5323.7 | 6488.1 | 7237.1 | 8502.6 |
Total Common Shares Outstanding | 634.806 | 629.106 | 623.106 | 627.306 | 624.3 | 624.1 |
Current Port. of LT Debt/Capital Leases | 598 | 0 | 0 | 0 | ||
Unrealized Gain (Loss) | -4.6 | -5 | 1.7 | 8.6 | -6.9 | |
Property/Plant/Equipment, Total - Gross | 1322.8 | 1652.7 | 2087.9 | 2293.3 | ||
Accumulated Depreciation, Total | -455.3 | -512.3 | -598.5 | -654.6 | ||
Deferred Income Tax | 124.9 | 171.7 | 214.4 | 259 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 3069.2 | 3322.9 | 3515.5 | 3180.7 | 3241.3 |
Cash and Short Term Investments | 1330.6 | 1561.2 | 1794.7 | 1466.8 | 1495.9 |
Cash & Equivalents | 1174.2 | 1312.8 | 1506.9 | 862.8 | 1030.9 |
Short Term Investments | 156.4 | 248.4 | 287.8 | 604 | 465 |
Total Receivables, Net | 664.3 | 700.3 | 664.2 | 664.9 | 686.2 |
Accounts Receivable - Trade, Net | 586.6 | 640.5 | 600.6 | 582.2 | 636.3 |
Total Inventory | 767.9 | 759.5 | 737.8 | 726.7 | 730.6 |
Prepaid Expenses | 77.3 | 68.6 | 76.9 | 85.2 | 94.1 |
Other Current Assets, Total | 229.1 | 233.3 | 241.9 | 237.1 | 234.5 |
Total Assets | 7213.7 | 7662.1 | 8160.3 | 8502.6 | 8419.9 |
Property/Plant/Equipment, Total - Net | 1506.4 | 1530.4 | 1549.4 | 1638.7 | 1642.3 |
Goodwill, Net | 1170.8 | 1171.8 | 1170.4 | 1167.9 | 1166.3 |
Intangibles, Net | 330.3 | 327 | 325.3 | 323.6 | 322 |
Long Term Investments | 802.2 | 1014.2 | 1282 | 1834.2 | 1623.7 |
Other Long Term Assets, Total | 334.8 | 295.8 | 317.7 | 357.5 | 424.3 |
Total Current Liabilities | 799 | 886.2 | 966.5 | 1032.3 | 949.9 |
Accounts Payable | 150.4 | 144.6 | 139.5 | 204.5 | 158.8 |
Accrued Expenses | 546.9 | 634.7 | 721.7 | 714.2 | 615.9 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 101.7 | 106.9 | 105.3 | 113.6 | 175.2 |
Total Liabilities | 2555.3 | 2528.8 | 2619 | 2666.7 | 2575 |
Total Long Term Debt | 595.2 | 595.4 | 595.5 | 595.7 | 595.9 |
Long Term Debt | 595.2 | 595.4 | 595.5 | 595.7 | 595.9 |
Deferred Income Tax | 224.2 | 234.2 | 245.4 | 259 | 270.7 |
Other Liabilities, Total | 936.9 | 813 | 811.6 | 779.7 | 758.5 |
Total Equity | 4658.4 | 5133.3 | 5541.3 | 5835.9 | 5844.9 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 637.5 | 640.1 | 641.2 | 642 | 642.9 |
Additional Paid-In Capital | 1496.8 | 1578.7 | 1643.1 | 1700.4 | 1769.4 |
Retained Earnings (Accumulated Deficit) | 4903.2 | 5392.7 | 5732.8 | 6068.1 | 6441.7 |
Treasury Stock - Common | -2206.7 | -2318.6 | -2320.4 | -2416.9 | -2822.5 |
Unrealized Gain (Loss) | 4.7 | 4.8 | 3 | -6.9 | -39.2 |
Other Equity, Total | -177.1 | -164.4 | -158.4 | -150.8 | -147.4 |
Total Liabilities & Shareholders’ Equity | 7213.7 | 7662.1 | 8160.3 | 8502.6 | 8419.9 |
Total Common Shares Outstanding | 621.8 | 623.1 | 624.2 | 624.1 | 621.4 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 569.5 | 583.6 | 722.2 | 1046.9 | 823.4 | 1503.1 |
Cash From Operating Activities | 704.4 | 1000.7 | 926.8 | 1179.4 | 1054.3 | 1732.1 |
Cash From Operating Activities | 71.2 | 81.9 | 77.4 | 89.3 | 107.2 | 134.8 |
Deferred Taxes | -37.4 | 17.8 | -27.3 | 12.1 | -49.4 | -41.4 |
Non-Cash Items | 35 | 83.2 | 197.1 | 235.4 | 130.9 | -9.7 |
Cash Taxes Paid | 99.9 | 143.7 | 223.7 | 61.5 | 197.9 | 182.5 |
Cash Interest Paid | 16.1 | 19.9 | 30.1 | 19.9 | 19.9 | 20.2 |
Changes in Working Capital | 66.1 | 234.2 | -42.6 | -204.3 | 42.2 | 145.3 |
Cash From Investing Activities | -211.7 | -647.2 | 76.7 | -595.8 | -531.1 | -1722.5 |
Capital Expenditures | -217.4 | -175.5 | -241.7 | -278.4 | -407.3 | -329.8 |
Other Investing Cash Flow Items, Total | 5.7 | -471.7 | 318.4 | -317.4 | -123.8 | -1392.7 |
Cash From Financing Activities | -268.5 | -473.2 | -1101.2 | -115.6 | -486.9 | -356.3 |
Financing Cash Flow Items | 68.4 | 0 | -15.4 | -2.8 | -1.2 | -0.3 |
Issuance (Retirement) of Stock, Net | -559 | -649.5 | -648.5 | -102.8 | -484.9 | -354.2 |
Issuance (Retirement) of Debt, Net | 222.1 | 176.3 | -437.3 | -10 | -0.8 | -1.8 |
Foreign Exchange Effects | -12.5 | 7.9 | -6.5 | -3 | -20.5 | 13.9 |
Net Change in Cash | 211.7 | -111.8 | -104.2 | 465 | 15.8 | -332.8 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 338.2 | 827.7 | 1167.8 | 1503.1 | 373.6 |
Cash From Operating Activities | 300.5 | 826.6 | 1358.5 | 1732.1 | 293.3 |
Cash From Operating Activities | 32.4 | 68.2 | 101.8 | 134.8 | 34.7 |
Deferred Taxes | 10.8 | 16.2 | 20.1 | -41.4 | -42.6 |
Non-Cash Items | 28.3 | -47.5 | -15.8 | -9.7 | 57 |
Changes in Working Capital | -109.2 | -38 | 84.6 | 145.3 | -129.4 |
Cash From Investing Activities | -49.7 | -379.2 | -756.6 | -1722.5 | 229.5 |
Capital Expenditures | -106 | -175.3 | -236 | -329.8 | -72.7 |
Other Investing Cash Flow Items, Total | 56.3 | -203.9 | -520.6 | -1392.7 | 302.2 |
Cash From Financing Activities | -274.3 | -333.3 | -294.3 | -356.3 | -368.1 |
Financing Cash Flow Items | -2.9 | -3 | -1 | -0.3 | 0 |
Issuance (Retirement) of Stock, Net | -271 | -328.7 | -291.6 | -354.2 | -368.1 |
Issuance (Retirement) of Debt, Net | -0.4 | -1.6 | -1.7 | -1.8 | 0 |
Foreign Exchange Effects | 14.2 | 11.6 | 12.1 | 13.9 | 13.2 |
Net Change in Cash | -9.3 | 125.7 | 319.7 | -332.8 | 167.9 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.1891 | 50629906 | 601760 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.113 | 31611698 | -370907 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.3359 | 26807322 | -90807 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 3.6712 | 22697460 | 293568 | 2022-09-30 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 2.7849 | 17217652 | 819288 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.3691 | 14647117 | 468181 | 2022-09-30 | LOW |
Brown Advisory | Investment Advisor/Hedge Fund | 2.3009 | 14225834 | 423457 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9297 | 11930529 | 199365 | 2022-09-30 | LOW |
Walter Scott & Partners Ltd. | Investment Advisor/Hedge Fund | 1.8866 | 11664308 | -1145504 | 2022-09-30 | LOW |
Sands Capital Management, LLC | Investment Advisor | 1.6831 | 10405902 | -1305885 | 2022-09-30 | LOW |
Fisher Investments | Investment Advisor/Hedge Fund | 1.2193 | 7538738 | 208057 | 2022-09-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.1967 | 7398732 | -543403 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.0615 | 6562640 | -2208605 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0484 | 6481823 | -233773 | 2021-12-31 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.9106 | 5629834 | -173381 | 2022-09-30 | LOW |
Nuveen LLC | Pension Fund | 0.8796 | 5438247 | -1014525 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.8792 | 5435848 | -1010885 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7709 | 4766457 | -217735 | 2022-09-30 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 0.723 | 4469833 | -657987 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7027 | 4344513 | -90711 | 2022-09-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Edwards Lifesciences Company profile
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Edwards Lifesciences Corp revenues increased 19% to $5.23B. Net income increased 83% to $1.5B. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 20% to $3.42B, Surgical Heart Valve Therapy segment increase of 17% to $889.1M, Critical Care segment increase of 15% to $834.9M, United States segment increase of 18% to $2.96B, Europe segment increase of 26% to $1.19B.
Equity composition
Common Stock $1 Par, 12/10, 350M auth., 117,100,000 issd. less 2,000 shs. in Treas. @ $102M. Insiders control 0.64%. 4/3/00,Company spun off from Baxter International. 05/10, 2-for-1 stock split. 12/15, 2-for-1 stock split.
Industry: | Advanced Medical Equipment & Technology (NEC) |
One Edwards Way
IRVINE
CALIFORNIA 92614
US
Income Statement
- Annual
- Quarterly
News

FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023
WTI, Gold, Silver – commodities weekly forecast for the week ahead
Strength to strength in the commodity space, however, topside exhaustion begins to creep in
13:53, 27 January 2023
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com